ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1602

Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: A Nationwide Analysis

Faria Sami1, Ahmad Basharat2, Shahzad Ahmed Sami3 and Saman Tanveer4, 1University of Alabama, Chicago, IL, 2Marshfield Clinic Health System, Marshfeild, WI, 3Trinity Health Oakland Hospital, Pontiac, 4John H. Stroger Jr. Hospital of Cook County, Chicago, IL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Comorbidity, Vasculitis

Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – ANCA-Associated Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune vasculitis of small to medium blood vessels, often causing multisystemic complications leading to increased morbidity and mortality. This study investigates various multisystemic complications among EGPA hospitalizations using the National Inpatient Sample (NIS) database.

Methods: Data from the NIS database 2016-2020 was utilized to identify all hospitalizations with a primary or secondary diagnosis of EGPA based on ICD-10 codes to include in the cohort. Demographic characteristics, length of hospital stay (LOS), and total hospital charges (THC) were analyzed. The prevalence of various complications was assessed and compared with non-EGPA hospitalizations.  Chi-square and Wilcoxon rank sum tests were done using STATA 17.0 were used to determine significant differences, with a threshold set at p < 0.05. Odds ratios (OR) from logistic analyses were reported.

Results: A total of 8,785 EGPA hospitalizations were included. Patients had a median age of 63 years, with a majority aged 40-60 years (46.70%). Females accounted for 58.00% of the cohort, and 72.74% were White (p < 0.001; OR: 1.44), while African American and Hispanic patients were underrepresented compared to non-EGPA hospitalizations (Table 1). EGPA patients had a longer median LOS (4 days vs. 3 days; p < 0.001) and higher THC ($42,664 vs. $32,666; p < 0.001). Medicare was the primary payer for 52.6% (p < 0.001). They also exhibited a higher Charlson Comorbidity Index (2.00 vs. 1.00; p < 0.001). Complications that were more prevalent in EGPA included: Acute myocarditis (AM) (1.02% vs. 0.02%; p < 0.001; OR: 58.34), atrial fibrillation/flutter (Afib/flut) (20.00% vs. 15.48%; p < 0.001; OR: 1.36), intracardiac thrombus (IT) (0.51% vs. 0.15%; p < 0.001; OR: 3.46), acute kidney injury (AKI) (20.77% vs. 15.82%; p < 0.001; OR: 1.39), chronic kidney disease (CKD) (20.94% vs. 17.13%; p < 0.001, OR 1.28), mononeuritis multiplex (MM) (2.45% vs < 0.01%, p < 0.001, OR 979), pulmonary hemorrhage (1.02% vs. 0.03%; p < 0.001; OR: 29.96),  pulmonary embolism/venous thromboembolism (PE/VTE) (3.76% vs. 2.06%; p < 0.001; OR: 1.86), nephritic syndrome (NS) (0.80% vs. 0.08%; p < 0.001; OR: 10.03), mechanical ventilation (5.63% vs. 3.54%; p < 0.01; OR: 1.63), and respiratory failure (28.40% vs. 12.38%; p < 0.001; OR: 2.81). No significant differences were found in ventricular tachycardia/ fibrillation (Vtach/fib), acute myocardial infarction (AMI), congestive heart failure (CHF), end-stage renal disease/dialysis-dependent (ESRD/DD), or inpatient mortality.

Conclusion: EGPA hospitalizations are characterized by longer stays, higher costs, and increased comorbidities compared to non-EGPA admits. They have significantly higher prevalence and odds of AM, Afib/flut, IT, AKI, CKD, MM, pulmonary hemorrhage, PE/VTE, NS, mechanical ventilation, and respiratory failure. These findings underscore the necessity of tailored care strategies for early complication detection and management in EGPA patients.

Supporting image 1

Table 1. Weighted Descriptive Characteristics of EGPA Hospitalizations from the 2016_2020 National Inpatient Sample (n=8785)

Supporting image 2

Table 2: Complications among EGPA Hospitalizations compared to non-EGPA hospitalizations


Disclosures: F. Sami: None; A. Basharat: None; S. Sami: None; S. Tanveer: None.

To cite this abstract in AMA style:

Sami F, Basharat A, Sami S, Tanveer S. Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: A Nationwide Analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/complications-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-patients-a-nationwide-analysis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complications-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-patients-a-nationwide-analysis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology